E2080-A001-502: An Open-Label, Non-Interventional Study of Rufinamide to Characterize Palatability and Acceptability of Rufinamide Oral Suspension in Subjects Aged 1 to 12 Years with Lennox-Gastaut Syndrome

Grants and Contracts Details

StatusFinished
Effective start/end date5/24/165/23/17

Funding

  • Eisai Incorporated: $2,032.00